Targeting DNA damage response pathways in cancer
FJ Groelly, M Fawkes, RA Dagg, AN Blackford… - Nature Reviews …, 2023 - nature.com
Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …
Patient-derived xenograft models in cancer therapy: technologies and applications
Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
[HTML][HTML] Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer
J Li, C Wu, H Hu, G Qin, X Wu, F Bai, J Zhang, Y Cai… - Cancer Cell, 2023 - cell.com
Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal …
H Hu, L Kang, J Zhang, Z Wu, H Wang… - The Lancet …, 2022 - thelancet.com
Background PD-1 blockade is highly effective in patients with mismatch repair-deficient or
microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 …
microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 …
Growth factors, PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?
C Stefani, D Miricescu, II Stanescu-Spinu… - International journal of …, 2021 - mdpi.com
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most
common cause of mortality and morbidity. The CRC incidence in adolescents, young adults …
common cause of mortality and morbidity. The CRC incidence in adolescents, young adults …
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Y Nakamura, A Kawazoe, F Lordick… - Nature reviews Clinical …, 2021 - nature.com
Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …
targeted and more effective treatments for individual patients with various types of solid …
[HTML][HTML] Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Molecular alterations in genes involved in DNA mismatch repair (MMR) promote cancer
initiation and foster tumour progression. Cancers deficient in MMR frequently show …
initiation and foster tumour progression. Cancers deficient in MMR frequently show …
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …